TSVT News and Press, 2seventy bio Inc. From 02/04/23

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentations. ...

Milestone payment is related to the establishment of 2seventy bio’s strategic partnership with JW Therapeutics Payment provides further validation of Medigene’s end-to-end platform MARTINSRIED, Germany and MUNICH, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Martinsried ...

Anticipate $470-$570M topline U.S. revenue Abecma (idecabtagene vicleucel) in 2023, shared equally with Bristol Myers Squibb (BMS) KarMMa-3 data to be presented at EBMT-EHA 5 th European CAR T-cell Meeting on February 10, 2023; 3L+ sBLA submission for Abecma targeted completio...

Collaboration Leverages 2seventy's Platform for T Cell Therapy Research and Development with Regeneron Antibodies and Bispecifics to Explore Multiplex Combination Approaches Regeneron Investing $20 million in 2seventy Equity; Regeneron to Fund 100% of Clinical Development Costs for Regene...

Summary Abecma U.S. sales in Q3 by BMS were $75 million. 2seventy bio is working on label expansion for Abecma. Platforms and pipeline imply strong growth during this decade. 2seventy bio ( TSVT ) is now a commercial-stage pharmaceutical company, as its cancer therapy ...

2seventy bio press release ( NASDAQ: TSVT ): Q3 GAAP EPS of -$1.76 beats by $0.09 . Revenue of $13.4M (-30.4% Y/Y) beats by $1.03M . For further details see: 2seventy bio GAAP EPS of -$1.76 beats by $0.09, revenue of $13.4M beats by $1.03M

Data from KarMMa-2 Cohorts 2a and 2c suggest potential for early treatment with Abecma in patients with second-line and newly diagnosed multiple myeloma Data suggest promising outcomes can be achieved treating patients with suboptimal response after transplant Resu...

Summary Chicago-based VectorBuilder, a gene therapy delivery CDMO, raised $57 million in a Series C round from China investors. JHM Biopharma completed a $28 million in a Series A1 round to support its biologic products for childhood genetic diseases, anti-aging, anti-virus and ne...

Initial focus on accelerating development of 2seventy bio’s MAGE-A4 program in solid tumors in China 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology co...

Summary Despite recent clinical and regulatory wins, bluebird bio's commercial success remains highly uncertain. Competition from next-generation gene therapies is closing in on lovo-cel (for Sickle Cell Disease), making a commercial success (if any) short-lived. Zynteglo's la...